Efficacy of various doses and schedules of second-generation tyrosine kinase inhibitors

Clinical Lymphoma and Myeloma

Volumn 8, Issue SUPPL. 3, 2008, Pages

  Bixby, Dale L ^a   Talpaz, Moshe ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Acute lymphocytic leukemia; Brc Abl; Chronic myeloid leukemia; Dasatinib; Imatinib; Nilotinib; Philadelphia chromosome

Indexed keywords

ABELSON KINASE; ALPHA INTERFERON; DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ACUTE LYMPHOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXPOSURE; HUMAN; IC 50; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PHILADELPHIA CHROMOSOME POSITIVE CELL; PLEURA EFFUSION; REVIEW;

EID: 43749104470     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2008.s.005     Document Type: Article

References (92)

1. ML Gishizky ON Witte Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro Science 256 1992 836 839
2. TL Holyoake X Jiang HG Jorgensen Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3 Blood 97 2001 720 728
3. J McLaughlin E Chianese O Witte In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome Proc Natl Acad Sci U S A 84 1987 6558 6562
4. MW Deininger JM Goldman JV Melo The molecular biology of chronic myeloid leukemia Blood 96 2000 3343 3356
5. S Faderl M Talpaz Z Estrov The biology of chronic myeloid leukemia N Engl J Med 341 1999 164 172
6. CL Sawyers Chronic myeloid leukemia N Engl J Med 340 1999 1330 1340
7. M Beran X Cao Z Estrov Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148) Clin Cancer Res 4 1998 1661 1672
8. E Buchdunger J Zimmermann H Mett Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative Cancer Res 56 1996 100 104
9. BJ Druker D Shu Buchdunger Effects of a Selective Inhibition of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med 2 1996 561 566
10. M Kalidas H Kantarjian M Talpaz Chronic Myelogenous Leukemia JAMA 286 2001 895 898
11. B Druker F Guilhot S O'Brien Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2006 2408 2417
12. Silver RT, Talpaz M, Sawyers CL, et al. Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials. Presented at: the American Society of Hematology 46th Annual Meeting and Exposition; December 9–12, 2004; Atlanta, GA. Abstract 23.
13. M Talpaz RT Silver BJ Druker Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study Blood 99 2002 1928 1937
14. L Crossman B Druker M Deininger hOCT 1 and resistance to imatinib Blood 106 2005 1133 1134
15. N Donato J Wu J Stapley BCR-ABL independence and Lyn kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571 Blood 101 2003 690 698
16. P le Coutre E Tassi M Varella-Garcia Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification Blood 95 2000 1758 1766
17. F Mahon M Deininger B Schultheis Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance Blood 96 2000 1070 1079
18. M Gorre M Mohammed K Ellwood Clinical resistance to STI- 571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 2001 876 880
19. M Azam RR Latek GQ Daley Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL Cell 112 2003 831 843
20. S Branford Z Rudzki S Walsh Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis Blood 102 2003 276 283
21. T O'Hare CA Eide MW Deininger Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia Blood 110 2007 2242 2249
22. C Roche-Lestienne V Soenen-Cornu N Grardel-Duflos Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment Blood 100 2002 1014 1018
23. N Shah J Nicoll B Nagar Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia Cancer Cell 2 2002 117 125
24. E Jabbour JE Cortes FJ Giles Current and emerging treatment options in chronic myeloid leukemia Cancer 109 2007 2171 2181
25. A Quintás-Cardama H Kantarjian J Cortes Flying under the radar: the new wave of BCR–ABL inhibitors Nat Rev Drug Discov 6 2007 834 838
26. RE Champlin E Jabbour J Cortes Treatment of patients (pts) with chronic myeloid leukemia (CML) and imatinib failure after developing BCR-ABL kinase mutations with allogeneic stem cell transplantation (ASCT) J Clin Oncol 24 18 suppl 2006 348s (Abstract 6545).
27. A Gratwohl J Hermans JM Goldman Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation Lancet 352 1998 1087 1092
28. HM Kantarjian TL Smith S O'Brien Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon- α therapy Ann Intern Med 122 1995 254 261
29. CA Schiffer R Hehlmann R Larson Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL Leukemia 17 2003 691 699
30. LJ Lombardo FY Lee P Chen Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin- 4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays J Med Chem 47 2004 6658 6661
31. PW Manley SW Cowan-Jacob J Mestan Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia Biochem Biophys Acta 1754 2005 3 13
32. MR Burgess BJ Skaggs NP Shah Comparative analysis of two clinically active BCR–ABL kinase inhibitors reveals the role of conformation-specific binding in resistance Proc Natl Acad Sci U S A 102 2005 3395 3400
33. C Gambacorti-Passerini M Gasser S Ahmed Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies Leukemia 19 2005 1267 1269
34. JS Tokarski JA Newitt CYJ Chang The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants Cancer Res 66 2006 5790 5797
35. M Talpaz N Shah H Kantarjian Dasatinib in imatinib-resistant Philadelphia chromosome–positive leukemias N Engl J Med 354 2006 2531 2541
36. M Talpaz HM Kantarjian R Paquette A phase I study of BMS- 354825 in patients with imatinib-resistant and intolerant chronic phase chronic myeloid leukemia (CML): results from CA180002 J Clin Oncol 23 16 suppl 2005 564s (Abstract 6519).
37. G Martinelli S Soverini G Rosti Dual tyrosine kinase inhibitors in chronic myeloid leukemia Leukemia 19 2005 1872 1879
38. T O'Hare DK Walters EP Stoffregen In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants Cancer Res 65 2005 4500 4505
39. T Oda C Heaney JR Hagopian Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia J Biol Chem 269 1994 22925 22928
40. M Sattler R Salgia Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells Leukemia 12 1998 637 644
41. A Hochhaus H Kantarjian M Baccarani Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy Blood 109 2007 2303 2309
42. A Hochhaus S Bradford J Radich Efficacy of dasatinib in chronic phase chronic myelogenous leukemia patients after imatinib failure according to baseline BCR-ABL mutations J Clin Oncol 25 18 suppl 2007 7023a
43. F Guilhot J Apperley DW Kim Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase Blood 109 2007 4143 4150
44. HM Kantarjian MJ Keating M Talpaz Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients Am J Med 83 1987 445 454
45. Y Canitrot D Lautier G Laurent Mutator phenotype of BCRABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta Oncogene 18 1999 2676 2680
46. H Salloukh P Laneuville Increase in mutant frequencies in mice expressing the BCR-ABL activated tyrosine kinase Leukemia 14 2000 1401 1404
47. J Cortes P Rousselot D Kim Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis Blood 109 2007 3207 3213
48. B Druker C Sawyers H Kantarjian Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N Engl J Med 344 2001 1038 1042 [published erratum in: N Engl J Med 2001; 345: 232.
49. OG Ottmann BJ Druker CL Sawyers A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosomepositive acute lymphoid leukemias Blood 100 2002 1965 1971
50. Y Hu Y Liu S Pelletier Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia Nat Genet 36 2004 453 461
51. O Ottmann H Dombret G Martinelli Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase II study Blood 110 2007 2309 2315
52. R Gallini JH Hendry G Molineux The effect of low dose rate on recovery of hematopoietic and stromal progenitor cells in γ-irradiated mouse bone marrow Radiat Res 115 1988 481 487
53. NG Testa TM Dexter Long-term hematopoietic damage: concepts, approaches, and results relevant to the study of environmental toxins Environ Health Perspec 82 1989 51 56
54. EL Atallah H Kantarjian S O'Brien Use of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in chronic phase (CML-CP) J Clin Oncol 25 18 suppl 2007 358s (Abstract 7005).
55. Jabbour E, Kantarjian H, Atallah E, et al. Impact of imatinib dose escalation on resistance and suboptimal responses to standard-dose therapy in patients (pts) with chronic myeloid leukemia (CML). Presented at: the American Society of Hematology 49th Annual Meeting and Exposition; December 8–11, 2007; Atlanta, GA. Abstract 1035.
56. HM Kantarjian M Talpaz S O'Brien Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia Blood 101 2003 473 475
57. H Kantarjian M Talpaz S O'Brien High dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia Blood 103 2004 2873 2878
58. JA Zonder P Pemberton H Brandt The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment Clin Cancer Res 9 2003 2092 2097
59. H Kantarjian R Pasquini N Hamerschlak Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of firstline imatinib: a randomized phase 2 trial Blood 109 2007 5143 5150
60. A Quintás-Cardama H Kantarjian D Jones Dasatinib (BMS- 354825) is active in Philadelphia chromosome–positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure Blood 109 2007 497 499
61. NP Shah DW Kim HM Kantarjian Dasatinib 50 mg or 70 mg BID compared to 100 mg or 140 mg QD in patients with CML in chronic phase (CP) who are resistant or intolerant to imatinib: one-year results of CA180034 J Clin Oncol 25 18 suppl 2007 358s (Abstract 7004).
62. R Pasquini OG Ottmann YT Goh Dasatinib 140 mg QD compared to 70 mg BID in advanced-phase CML or Ph(+) ALL resistant or intolerant to imatinib: One-year results of CA180-035 J Clin Oncol 25 18 suppl 2007 363s (Abstract 7025).
63. DL White VA Saunders P Dang OCT-1–mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib Blood 108 2006 697 704
64. DL White VA Saunders P Dang Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity. Higher doses of imatinib may overcome the negative impact of low OCT-1 Activity Blood 110 2007 4064 4072
65. Lee FY, Wen M-L, Bhide R, et al. Dasatinib (BMS-354825) overcomes multiple mechanisms of imatinib resistance in chronic myeloid leukemia (CML). Presented at: Presented at: the American Society of Hematology 47th Annual Meeting and Exposition; December 10–13,2005; Atlanta, GA. Abstract 1994.
66. S Picard K Titier G Etienne Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standarddose imatinib in chronic myeloid leukemia Blood 109 2007 3496 3499
67. BMF Mow J Chandra PA Svingen Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro Blood 99 2002 664 671
68. M Golemovic S Verstovsek F Giles AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia Clin Cancer Res 11 2005 4941 4947
69. S Verstovsek M Golemovic H Kantarjian AMN107, a novel aminopyrimidine inhibitor of p190 BCR-ABL activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells Cancer 104 2005 1230 1236
70. E Weisberg PW Manley W Breitenstein Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl [published erratum in: Cancer Cell 2005; 7:399] Cancer Cell 7 2005 129 134
71. E Weisberg P Manley J Mestan AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL Br J Cancer 94 2006 1765 1769
72. H Kantarjian F Giles L Wunderle Nilotinib in imatinib-resistant CML and Philadelphia chromosome–positive ALL N Engl J Med 354 2006 2542 2551
73. H Kantarjian F Giles N Gattermann Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance Blood 110 2007 3540 3546
74. S Le Gouill P Talmant N Milpied Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia J Clin Oncol 18 2000 1533 1538
75. E Jabbour J Cortes F Giles Preliminary activity of nilotinib (AMN107), a novel selective potent oral Bcr-Abl tyrosine kinase Inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP) Blood 108 2006 616a (Abstract 2172).
76. P le Coutre N Gattermann A Hochhaus A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP) J Clin Oncol 25 18 suppl 2007 363s (Abstract 7026).
77. R Larson O Ottman H Kantarjian A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL) J Clin Oncol 25 18 suppl 2007 363s (Abstract 7040).
78. FJ Giles P le Coutre K Bhalla A phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib J Clin Oncol 25 18 suppl 2007 367s (7038).
79. M Deininger M Schleuning M Greinix The effect of prior exposure to imatinib on transplant-related mortality Haematologica 91 2006 452 459
80. D Thomas S Faderl J Cortes Treatment of Philadelphia chromosome– positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate Blood 103 2004 4307 4396
81. M Yanada J Takeuchi I Sugiura High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group J Clin Oncol 24 2006 460 466
82. E Jabbour J Cortes H Kantarjian Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia Cancer 110 2007 340 344
83. MH Cohen ML Moses R Pazdur Gleevec™ for the Treatment of Chronic Myelogenous Leukemia: U.S. Food and Drug Administration Regulatory Mechanisms, Accelerated Approval, and Orphan Drug Status Oncologist 7 2002 390 392
84. A Jemal R Siegel E Ward Cancer statistics, 2006 CA Cancer J Clin 56 2006 106 130
85. E Jabbour J Cortes H Kantarjian Optimal first-line treatment of chronic myeloid leukemia – how to use imatinib and what role for newer drugs? Oncology 21 2007 653 672
86. J Kling Bundling next-generation cancer therapies for synergy Nat Biotech 24 2006 871 878
87. M Baccarani G Saglio J Goldman Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood 108 2006 1809 1820
88. C Blasdel MJ Egorin TF Lagattuta Therapeutic drug monitoring in CML patients on imatinib Blood 110 2007 1699 1701
89. F Mahon S Picard G Marit Use of therapeutic drug monitoring in CML patients on imatinib Blood 110 2007 1701
90. S Chu H Xu N Shah Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment Blood 105 2005 2093 2098
91. NP Shah BJ Skaggs S Branford Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency J Clin Invest 117 2007 2562 2569
92. J Cortes E Jabbour H Kantarjian Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors Blood 110 2007 4005 4011